News

The preliminary data, which are from an interim analysis of Wyeth’s ongoing phase III clinical trial of temsirolimus (CCI-779) in advanced renal cell carcinoma (RCC), showed that single-agent

The licensing agreement follows a long-standing collaboration between both parties on GSK’s investigational MAGE-A3 antigen specific cancer immunotherapeutic (ASCI) in non-small cell lung cancer (NSCLC). This novel cancer

Both companies will contribute expertise and intellectual property relating to JAK3 inhibitors for the purpose of bringing compounds into the clinic. Novartis will assume responsibility for product development

Panitumumab is an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr). Results from both studies suggest that the antitumor activity of panitumumab was

New data from a five-year update from the bone sub protocol of the ATAC trial confirm that women who have a normal bone mineral density (BMD) at the

In the study, the combination of Tykerb (lapatinib ditosylate) and Roche's Xeloda (capecitabine) versus capecitabine alone nearly doubled time to progression (36.9 weeks in the combination arm versus

The committee voted in favor of accelerated approval of the drug for the treatment of adults in all phases of chronic myeloid leukemia (CML) with resistance or intolerance

Bayer previously extended the timeframe on its E86 cash per share offer for Schering by an extra two weeks in order to allow it extra time to acquire

Preliminary results from the phase I hematology study are published in the 2006 American Society of Clinical Oncology annual meeting proceedings. An anti-leukemia effect was seen in two